Clinical Trials

46 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Urinary Bladder Neoplasms

NCT05092373 2026-01-14

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Phase 1 Recruiting

43 enrolled

Breast Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Endometrial Neoplasms

NCT02989584 2026-01-07

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

Phase 1/2 Active not recruiting

54 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

161 enrolled

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT05287464 2025-11-26

International Multicentric Study ARON-1

Recruiting

1,220 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Carcinoma, Renal Cell

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT03693014 2025-10-06

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

69 enrolled

GenitourinaryThoracic

Urinary Bladder Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis

NCT05312671 2025-06-29

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

63 enrolled

Urinary Bladder Neoplasms

NCT03821246 2025-05-15

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

68 enrolled

Prostatic Neoplasms

NCT05168618 2025-05-07

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

33 enrolled

Prostatic Neoplasms

NCT04262154 2025-04-27

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

28 enrolled

Prostatic Neoplasms

NCT04602078 2025-04-24

AUREA

82 enrolled 20 charts

Carcinoma, Transitional Cell, Neoplasm Metastasis, Neoplasms

NCT03093922 2025-04-22

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

32 enrolled

Carcinoma, Transitional Cell

NCT03024437 2025-03-20

Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

Phase 1/2 Terminated

31 enrolled 19 charts

Kidney Neoplasms, Neoplasm Metastasis

NCT02662309 2025-03-10

ABACUS

96 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04322643 2025-02-25

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

Phase 2 Terminated

4 enrolled 10 charts

Phase 3 Active not recruiting

Carcinoma, Transitional Cell

NCT04637594 2025-01-15

IMAGINE

3 enrolled

Carcinoma, Transitional Cell

NCT03272217 2025-01-07

Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer

Phase 2 Terminated

16 enrolled 12 charts

Carcinoma, Transitional Cell

NCT04812366 2024-12-16

GUNS

315 enrolled

Prostatic Neoplasms

NCT04289779 2024-12-04

ABATE

46 enrolled

Urinary Bladder Neoplasms

NCT02451423 2024-05-31

Neoadjuvant Atezolizumab in Localized Bladder Cancer

23 enrolled 14 charts

Carcinoma, Transitional Cell

NCT03511391 2024-01-23

CHEERS

DermatologicGenitourinaryHead & NeckThoracic

99 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT06169904 2023-12-14

B7-Family Score in Urothelial Carcinoma

Completed

215 enrolled

GenitourinaryHead & NeckThoracic

Carcinoma, Transitional Cell

NCT05259319 2023-10-17

IMMUNOs-SBRT

Phase 1 Unknown

92 enrolled

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Neoplasms

NCT03737123 2023-09-13

Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Phase 2 Terminated

6 enrolled 18 charts

BreastGenitourinaryThoracic

Carcinoma, Transitional Cell

NCT04639245 2023-08-03

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Phase 1/2 Terminated

1 enrolled 6 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03359239 2023-05-16

Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer

Phase 1 Completed

10 enrolled